Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

ATHA

Athira Pharma (ATHA)

Athira Pharma Inc
Da:
Ordina per:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATHA
DataOraFonteTitoloSimboloCompagnia
12/03/202522:20Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ATHAAthira Pharma Inc
04/03/202522:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATHAAthira Pharma Inc
27/02/202522:30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ATHAAthira Pharma Inc
27/02/202522:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ATHAAthira Pharma Inc
27/02/202522:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATHAAthira Pharma Inc
27/02/202522:05GlobeNewswire Inc.Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business UpdatesNASDAQ:ATHAAthira Pharma Inc
03/01/202502:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ATHAAthira Pharma Inc
06/12/202423:30GlobeNewswire Inc.Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MNDNASDAQ:ATHAAthira Pharma Inc
07/11/202422:05GlobeNewswire Inc.Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business UpdatesNASDAQ:ATHAAthira Pharma Inc
29/10/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATHAAthira Pharma Inc
22/10/202413:00GlobeNewswire Inc.Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 MeetingNASDAQ:ATHAAthira Pharma Inc
21/10/202412:24Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATHAAthira Pharma Inc
04/10/202401:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATHAAthira Pharma Inc
17/09/202415:00GlobeNewswire Inc.Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative DiseasesNASDAQ:ATHAAthira Pharma Inc
04/09/202411:50IH Market NewsNvidia Subpoenaed by DOJ, Athira Pharma Shares Plunge 71% After Study Fails, Zscaler Falls 15% Post-EarningsNASDAQ:ATHAAthira Pharma Inc
03/09/202422:01GlobeNewswire Inc.Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s DiseaseNASDAQ:ATHAAthira Pharma Inc
09/08/202422:05Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:ATHAAthira Pharma Inc
01/08/202422:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATHAAthira Pharma Inc
01/08/202422:05GlobeNewswire Inc.Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business UpdatesNASDAQ:ATHAAthira Pharma Inc
31/07/202414:05GlobeNewswire Inc.Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024NASDAQ:ATHAAthira Pharma Inc
12/06/202413:00GlobeNewswire Inc.Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease PatientsNASDAQ:ATHAAthira Pharma Inc
11/06/202413:00GlobeNewswire Inc.Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)NASDAQ:ATHAAthira Pharma Inc
29/05/202413:00GlobeNewswire Inc.Athira Pharma to Participate in Upcoming June ConferencesNASDAQ:ATHAAthira Pharma Inc
17/05/202423:00GlobeNewswire Inc.Athira Pharma Announces Proposed Settlement of Stockholder Derivative ActionNASDAQ:ATHAAthira Pharma Inc
15/05/202422:05GlobeNewswire Inc.Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business UpdatesNASDAQ:ATHAAthira Pharma Inc
02/05/202413:00GlobeNewswire Inc.Athira Pharma to Participate in Upcoming May ConferencesNASDAQ:ATHAAthira Pharma Inc
15/04/202413:00GlobeNewswire Inc.Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical OfficerNASDAQ:ATHAAthira Pharma Inc
11/04/202413:00GlobeNewswire Inc.Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s DiseaseNASDAQ:ATHAAthira Pharma Inc
03/04/202413:00GlobeNewswire Inc.Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:ATHAAthira Pharma Inc
08/03/202413:00GlobeNewswire Inc.Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International ConferenceNASDAQ:ATHAAthira Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ATHA